Clinical Trials Search at Vanderbilt-Ingram Cancer Center
VANISH 2- Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2
Not Available
III
Kanagasundram, Arvindh
CRE-CHF0001
SOS-AMI - Protocol ID-07-076A301 Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Not Available
III
Defilippis, Andrew
CRE-GEN0002
DEFINE-HT - DevelopmEnt of non-invasive cell-Free DNA to supplant INvasivE biopsy in Heart Transplantation
Not Available
III
Schlendorf, Kelly
CRE-CHF0010
Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis
Not Available
III
Wheeler, Allison
NCT05878938
NCBH2302-FRONTIER5
OCEANIC-AF - A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke
Not Available
III
Montgomery, Jay
CRE-ARR0018
A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension
Not Available
III
Not Available
NCT02910414
CRE-INT0003
The RADIANCE-HTN; Study A study of the ReCor Medical Paradise System in Clinical Hypertension
Not Available
III
Fong, Pete
NCT02649426
CRE-INT0001
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Multiple Cancer Types
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Neuro-Oncology,
Pediatrics
III
Esbenshade, Adam
NCT04939597
COGACCL2031
Studying the Effect of Levocarnitine in Protecting the Liver from Chemotherapy for Leukemia or Lymphoma
Multiple Cancer Types
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Leukemia,
Pediatric Leukemia
III
Borinstein, Scott
NCT05602194
VICC-NTPED23475